CEACAM5 and urinary bladder carcinoma: Research conducted in clinical chemistry in 2023 showed that NMP22, BTA stat, and uPA urine biomarkers were better than CEA and CYFRA 21-1 blood markers in the differentiation of bladder cancer patients and controls, especially among high-risk populations (97).